RECORDATI ANNOUNCES STRATEGIC COLLABORATION WITH MODERNA TO DEVELOP AND COMMERCIALIZE WORLDWIDE mRNA 3927 FOR THE TREATMENT OF PROPIONIC ACIDEMIA mRNA-3927 is a strong strategic fit with Recordati’s rare Metabolic portfolio Collaboration combines Moderna’s expertise in mRNA technology for rare metabolic disorders with Recordati’s established global rare disease commercial infrastructure Moderna will continue to lead development for mRNA-3927, and if approved, Recordati will lead global commercialization efforts Milan, 29 January 2026 – Recordati today announced that it has entered into a...
RECORDATI ANNUNCIA UNA COLLABORAZIONE STRATEGICA CON MODERNA PER SVILUPPARE E COMMERCIALIZZARE A LIVELLO GLOBALE mRNA-3927 PER IL TRATTAMENTO DELL’ACIDEMIA PROPIONICA mRNA-3927 si inserisce strategicamente nel portafoglio delle malattie rare metaboliche di Recordati La collaborazione unisce l’expertise di Moderna nella tecnologia mRNA per i disturbi metabolicirari con la solida infrastruttura commerciale globale di Recordati nelle malattie rare Moderna continuerà a guidare lo sviluppo di mRNA-3927 e, in caso di approvazione, Recordati guiderà la commercializzazione a livello globale Mila...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.